Title
Category
Credits
Event date
Cost
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
This course will provide you with valuable updates in Acne Vulgaris presented at the 28th Annual Masters of Pediatric Dermatology and the 18th Annual South Beach Symposium:Acne Diagnosis and Treatment in WomenTherapeutic Advancements in Acne & Rosacea TherapyLatest Developments in Lasers and Light Therapies for AcneControversies in Oral Therapy for AcnePediatric Perspective: Video and slide highlights will also be included from the Masters of Pediatric Dermatology conference for learners interested in the pediatric perspective.
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
This course will provide you with valuable updates in Atopic Dermatitis (AD) presented at the 28th Masters of Pediatric Dermatology and the 18th Annual South Beach Symposium from high caliber Dermatology physicians below:
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
The ever-increasing presence of a variety of dermatologic conditions across the lifespan, including in neonates, children, and adolescents continues to be a major challenge for healthcare providers in the United States.  Current estimates predict that up to 30% of primary care visits in the US involve a skin-related issue, with some of the most common conditions including atopic dermatitis, seborrheic dermatitis, contact dermatitis, acne, neonatal rashes, and sunburn among others (Castelo-Soccio 2017).  There is a shortage of pediatric dermatologists in the United States, and more often the
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Diabetes increases the risk of cardiovascular and thrombotic adverse events in patients with CAD and PAD compared to patients with these conditions and no concomitant diabetes. As such, current antithrombotic strategies to prevent adverse events in these high-risk patients may not be adequate, and several recently-completed and ongoing clinical trials are evaluating the efficacy and safety of additional approaches, including the use of more aggressive and specific antithrombotic agents in this setting.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Patients with diabetes and PAD, particularly those with concomitant polyvascular disease, are at a greater risk for future adverse cardiovascular and limb events.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Lowering LDL-C effectively and safely is crucial in preventing ASCVD events. Even with the advances in LDL-C-lowering therapy, there is considerable residual risk due to suboptimal adherence, clinical efficacy, or clinical inertia, which increases the chances of serious adverse CV events. Several new and emerging agents may help address these gaps in the near future, and clinicians need to be aware of these new approaches and their potential role in the treatment of high-risk patients with elevated LDL-C.
  • CMHC
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Patient with ILDs, especially those with a progressive fibrosis phenotype, maybe at a greater risk for having worse outcomes with COVID-19, including during and post-COVID-19 infection. However, the management of patients with PF-ILDs and COVID-19 is not clear, including the potential management of COVID-19 related lung injury and fibrosis, as well as the overall management of ILDs in the COVID-19 era. During this webcast, experts will discuss these gaps and the implications of COVID-19 in the management of patients with ILDs and PF-ILD.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
During this activity, multidisciplinary experts discuss the evidence with SGLT-2 inhibitors in reducing cardiorenal risk in patients with and without T2DM, as well as offer additional clinical pearls about their application across specialties.This interactive monograph is organized in an easily digestible format, containing a mix of visuals, audio, video, resources, patient cases, as well as news articles and publications, in order to better facilitate the interpretation of the journey of SGLT-2 inhibitors across trials and to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
The 2020 Annual CMHC On Demand - Evolving Paradigms in Cardiometabolic Care: Disparities & Advancements will translate the latest cutting-edge medical research into practical, clinical strategies for preventing, delaying, diagnosing, treating, and managing the whole spectrum of cardiometabolic disorders. The goal is to provide the medical community with evidence-based interventions that they can apply immediately in clinical practice to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Familial hypercholesterolemia (FH) remains underdiagnosed and undertreated, which increases ASCVD risk, morbidity and mortality in HF patients.In addition, the relatively low insurance approvals for newer LDL-C lowering agents, even for high-risk FH patients, has limited patients’ access to these necessary therapies, increasing their risk for morbidity and mortality. These challenges in diagnosis and treatment are even more apparent in racial and ethnic minorities.

Pages